INMB Stock Analysis: Buy, Sell, or Hold?
INMB - INmune Bio Inc. Common stock
$2.32
0.16 (7.41%)
▲
5d:
+6.91%
30d:
+34.88%
90d:
+61.11%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When INMB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: INMB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: INMB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: INMB is currently trading at $2.32, which is considered extended relative to its 30-day fair value range of $1.77 to $2.14.
Technical Outlook: Technically, INMB is in a strong uptrend. The price is approaching resistance at $2.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: INMB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+201.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, INMB is in a strong uptrend. The price is approaching resistance at $2.34. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 7.4% recently.
Market Sentiment: INMB scores 5/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $7.00 (+201.7%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.77 -
$2.14
Company Quality Score
26/100
(SELL)
Options IV Signal
58th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
35.4%
All Signals
- BEARISH: Price extended above range (+8.4% above its trading range)
- NEUTRAL: Options fairly priced (IV 58th percentile)
- BEARISH: Weak technical setup (5/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.4%)
- BULLISH: Trading 201.7% below Wall St target ($7.00)
- WARNING: Composite score 26/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$1.77 -
$2.14
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$0.51
(21.9%)
Support & Resistance Levels
Support Level
$2.01
Resistance Level
$2.34
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.42
Wall Street Target
$7.00
(+201.7%)
Revenue Growth (YoY)
257.1%
Share & Embed Analysis
Last updated: August 24, 2026 8:03 AM ET
Data refreshes hourly during market hours. Next update: 9:03 AM
Data refreshes hourly during market hours. Next update: 9:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INMB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$127 | 41 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
